

Cancer Care Quality Program

Biomarker Entry

Identifying treatment regimens that are adherent with Carelon Medical Benefits Management Pathways is an important quality indicator for your practice.

Clinical and laboratory information is crucial to identify on-pathway regimens. Please see below for basic information that is required for some common cancers

Breast Cancer

- Estrogen receptors, Progesterone receptors
- HER2 over-expression
- PDL-1 expression (CPS, Combined Positive Score): if using pembrolizumab
- PIK3CA Mutation (if using alpelisib)

Non-Small Cell Lung Cancer

- Squamous cell cancer OR non-squamous cancer (including adenocarcinoma)
- PDL-1 Expression (%)
- ALK Fusion, EGFR mutation, ROS1 rearrangement: Present or absent

Colon Cancer

- RAS: mutation or wild type
- MSI: high or low (or MMR deficient or proficient)

Prostate Cancer

- Hormone sensitive or hormone-resistant

Ovarian Cancer

- Platinum sensitive or platinum resistant

Multiple Myeloma

- Transplant eligible or transplant ineligible

Melanoma

- BRAF mutation: positive or negative

Gastric/Gastroesophageal Cancer

- HER2 over expression
- PDL-1 Expression (CPS: Combined positive score)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

- 17p deletion (positive or negative)
- TP53 mutation present or absent

For more information:

- ❖ Our dedicated oncology provider website offers you all the tools and information you.
- ❖ To access, go to www.cancerqualityprogram.com.

